MYGN — MYRIAD GENETICS INC
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 899923 ·
Last close
$5.54
Market Cap
$530.18M
52W High
$8.09
52W Low
$2.74
ADV30
2,649,513
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 200,400,000 | 137,600,000 | -25,300,000 | -34,100,000 | 673,700,000 | 124,400,000 | 336,300,000 |
| Dec 2025 | 209,800,000 | 146,800,000 | -3,000,000 | -7,900,000 | 706,600,000 | 149,600,000 | 338,600,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$2,400,000
Investing CF
$-25,600,000
Financing CF
$47,600,000
CapEx
$-25,600,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.36
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,156,800,000
Inventory
$27,900,000
Receivables
$123,800,000
ST Investments
—
EBIT TTM
$-386,000,000
Pretax Income TTM
$-399,800,000
Interest Exp TTM
$13,800,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$803,600,000
EBITDA
$-58,300,000
Free Cash Flow
$3,587,500
Enterprise Value
$668,844,032
Total Cash
$107,100,000
Total Debt
$209,400,000
Shares Out
95,700,000
Trailing EPS
$-1.35
Book Value
$2.81
ROE
-40.2%
ROA
-10.0%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 824,500,000 | -67,800,000 | -365,900,000 | 706,600,000 | 338,600,000 | 368,000,000 | 1,800,000 |
| Dec 2024 | 837,600,000 | -88,000,000 | -127,300,000 | 1,027,600,000 | 326,500,000 | 701,100,000 | -8,700,000 |
| Dec 2023 | 753,200,000 | -144,600,000 | -263,300,000 | 1,146,500,000 | 363,300,000 | 783,200,000 | -110,900,000 |
| Dec 2022 | 678,400,000 | -123,700,000 | -112,000,000 | 1,198,700,000 | 312,900,000 | 885,800,000 | -106,300,000 |
TTM Snapshot
Revenues TTM
$806,600,000
NetIncome TTM
$-112,600,000
OpCashFlow TTM
—
Assets (Latest)
$638,900,000
Forward EPS
$-0.59
Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $5.53 · call volume: 214 · put volume: 22Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NRC | NRC HEALTH | $549.32M | $25.89 | — |
| TKNO | Alpha Teknova, Inc. | $481.21M | $7.65 | — |
| QUIT | ACHIEVE LIFE SCIENCES, INC. | $630.99M | $6.12 | — |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $666.81M | $6.06 | — |
| QDEL | QuidelOrtho Corp | $677.21M | $9.87 | — |
News headlines (Yahoo Finance, 1h cache)
Myriad Genetics Expands SRL Partnership in Japan to Support Future Growth
2026-11-17 14:05 · Yahoo
Carrier Screening - Global Strategic Business Report 2026: Secure Your Share of a $7.6 Billion Market by 2032 | Features Competitive Intelligence on Illumina, Natera, BGI Genomics, and Myriad Genetics
2026-11-11 14:25 · Yahoo
Myriad Genetics’s Q3 2026 earnings call: our top 5 analyst questions
2026-11-08 23:33 · Yahoo
Myriad Genetics (MYGN) Q3 2026 Earnings Call Transcript
2026-11-05 18:50 · Yahoo
Myriad Genetics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 13:30 · Yahoo
Myriad Genetics Inc (MYGN) Q3 2026 Earnings Call Highlights: Revenue Guidance Raised as ...
2026-11-05 09:13 · Yahoo
Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates
2026-11-04 23:45 · Yahoo
Myriad: Q3 Earnings Snapshot
2026-11-04 23:17 · Yahoo
Myriad Genetics Q3 Earnings Call Highlights
2026-11-04 23:14 · Yahoo
Myriad Genetics (NASDAQ:MYGN) reports upbeat Q3 2026, stock jumps 10.7%
2026-11-04 21:34 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.